Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies

Hamacher, Thomas; Schinzel, M; Schölzel-Klatt, A; Hm, Neff; Maier, Hubert; Schlaffer, G.; Beausencourt, E; Jutte, Max Ernest; Scholz, Roy O.; Lorger, C; Wc, Stewart

doi:10.1136/bjo.2004.043232

Cited by 31 publications

(29 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We found a statistically significant mean IOP reduction of 2.6 mmHg after an average of 4.1 months of followup; it is possible that some of the observed reduction may be caused by the regression towards the mean effect, however the observed magnitude is similar to reductions reported in other studies 7,8,[11][12][13] . For example, Hamacher et al 11 found that IOP levels decreased by a mean of 3.7 AE 4.5 mmHg (p50.001) in 53 patients followed for at least 2 months after changing from LM to LTFC. Similarly, a 3-month study 12 that included 54 patients changed from LM to LTFC found an average incremental IOP reduction of 2.9 AE 3.7 mmHg (p50.001).…”

Section: Discussionsupporting

confidence: 70%

Changes in intraocular pressure following a switch from latanoprost monotherapy to latanoprost/timolol fixed combination therapy in patients with primary open-angle glaucoma or ocular hypertension: results from a clinical practice database

Lazaridou

Montgomery

et al. 2008

Current Medical Research and Opinion

View full text Add to dashboard Cite

A B S T R A C TAims: To assess the incremental change in intraocular pressure (IOP) levels in patients with primary open-angle glaucoma or ocular hypertension, insufficiently treated with topical ocular hypotensive monotherapy or combination therapy and changed to the latanoprost/timolol fixedcombination therapy (LTFC).Methods: The glaucoma database of the Glasgow Royal Infirmary was reviewed retrospectively to identify patients ! 18 years of age with primary open-angle glaucoma or ocular hypertension in at least one eye who had been switched to LTFC from a previous monotherapy or combination therapy. Ninety patients were identified, and 59 (66%) had changed to LTFC from latanoprost monotherapy (LM). The analysis focused on this subgroup because few patients were changed from any other single therapy.At least one documented patient visit following the change to LTFC was required. The within-subject difference in IOP levels (IOP on LM-IOP on LTFC) was calculated for each case, and the statistical significance of the mean change in IOP was analysed using a 2-sided Student's paired t-test with a 0.05 a level.Results: The mean decrease in IOP after changing to LTFC from LM was 2.6 mmHg (95% confidence interval ¼ 1.6, 3.6), from 21.4 (SD ¼ 3.5) mmHg to 18.8 (SD ¼ 4.2) mmHg (p ¼ 0.002).Conclusions: LTFC provides significant incremental IOP reduction in patients with primary open-angle glaucoma or ocular hypertension who require additional IOP reduction following treatment with LM.

show abstract

Section: Discussionsupporting

confidence: 70%

Changes in intraocular pressure following a switch from latanoprost monotherapy to latanoprost/timolol fixed combination therapy in patients with primary open-angle glaucoma or ocular hypertension: results from a clinical practice database

Lazaridou

Montgomery

et al. 2008

Current Medical Research and Opinion

View full text Add to dashboard Cite

show abstract

“…These data are seemingly inconsistent, however, with those of previous studies which showed switching patients from DTFC to latanoprost also provided a decrease in pressure (Zimmerman & Stewart 2003;Bayer et al 2004;Haverkamp et al 2004;Hamacher et al 2004). The reason why patients would have further reductions in pressure depending on the order in which the medicines were prescribed is not clear, but it may be based on several potential mechanisms: firstly, patients may have a true increase in efficacy with the new medication.…”

Section: Discussionmentioning

confidence: 84%

“…Trials in the USA and Germany have shown generally that patients on other mono-and adjunctive therapies, including DTFC, experienced a further statistical reduction in IOP when they switched to latanoprost or latanoprost ⁄ timolol fixed combination (Zimmerman & Stewart 2003;Bayer et al 2004;Haverkamp et al 2004;Hamacher et al 2004).…”

Section: Discussionmentioning

confidence: 99%

“…However, in several open-label trials, in which patients on the fixed combination were switched to latanoprost, the prostaglandin analogue was found to be more effective (Zimmerman & Stewart 2003;Bayer et al 2004;Haverkamp et al 2004;Hamacher et al 2004). This design attempted to emulate physician practice by changing therapy, as opposed to assigning medication, as one would in a well controlled, double-masked trial.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Success rates for switching to dorzolamide/timolol fixed combination in timolol responders who are insufficiently controlled by latanoprost monotherapy

Sonty

Henry²,

Sharpe

et al. 2008

Acta Ophthalmologica

View full text Add to dashboard Cite

ABSTRACT.Purpose: We aimed to investigate the safety and efficacy of dorzolamide ⁄ timolol fixed combination (DTFC) in timolol responders with ocular hypertension or open-angle glaucoma who switched to DTFC because of insufficient control on latanoprost. Methods:We carried out a prospective, open-label cohort study with an active-historical control in which qualifying patients must have been treated with latanoprost monotherapy for at least 4 weeks, must have demonstrated insufficiently controlled intraocular pressure (IOP) ( ‡ 19 mmHg at 08.00 hours), and must have shown a decrease in IOP at 2 hours after timolol instillation of ‡ 3 mmHg or ‡ 15%. Patients then began DTFC dosed at 08.00 hours and 20.00 hours and discontinued latanoprost. Patients were evaluated again after 4 and 12 weeks.Results: In 57 patients IOP was further reduced by 2.4 ± 3.3 mmHg at 08.00 hours (p < 0.0001) and by 3.5 ± 3.3 mmHg at 10.00 hours (p < 0.0001) after switching to DTFC. Responses to the Comparison of Ophthalmic Medications for Tolerability (COMTol) questionnaire showed no difference between DTFC and latanoprost for in terms of overall preference, typical daily activities, limitation of activities, compliance, satisfaction or quality of life (p > 0.05). However, greater frequency in burning and ⁄ or stinging (p < 0.0001) and bitter taste (p < 0.0001) were observed with DTFC, whereas unusual taste (p = 0.02) and itchy eyes (p = 0.05) were associated with latanoprost.Conclusions: This study suggests that patients who are insufficiently controlled on latanoprost monotherapy, and who are timolol responders, can generally achieve further IOP reduction and similar tolerance levels when changed to DTFC.

show abstract

“…However, there is not necessarily agreement as to whether DTFC would reduce the IOP after switching. For example, some studies have shown a decrease of IOP after switching from DTFC to latanoprost 16–19. To explain this apparent inconsistency, two possibilities can be suggested.…”

Section: Discussionmentioning

confidence: 99%

Effect of 3 years of treatment with a dorzolamide/timolol (1%/0.5%) combination on intraocular pressure

Takeda¹,

Mimura²,

Matsubara³

2014

OPTH

View full text Add to dashboard Cite

PurposeWe aimed to evaluate the effect on the intraocular pressure (IOP) of a dorzolamide/timolol (1%/0.5%) fixed combination (DTFC) ophthalmic agent for 3 years.ParticipantsA total of 19 consecutive patients who had previously been treated with mono-therapy or any combination of a beta-blocker, carbonic anhydrase inhibitor, or prostaglandin analog, for primary open-angle glaucoma (POAG) (n=5) or normal tension glaucoma (N=14) were enrolled.MethodsPatients were switched to DTFC from their prior glaucoma therapy. The IOP was measured at intervals of 4–6 weeks for 3 years. Treatment failure was defined as an increase of IOP by ≥10% from baseline after switching to DTFC.ResultsThe average IOP decreased significantly from 14.1±2.9 mmHg at baseline to 12.2±2.2, 11.8±2.4, 12.1±2.5, 11.6±1.8, and 12.1±2.7 mmHg at 3, 6, 12, 24, and 36 months, respectively, after switching therapy (all P<0.05). The mean percent decrease of IOP was 12.0%±13.0%, 14.5%±14.2%, 12.2%±18.7%, 16.0%±12.8%, and 12.8%±15.2% at 3, 6, 12, 24, and 36 months, respectively, after switching. Univariate or multivariate analysis revealed the percent decrease of IOP was associated with the type of glaucoma (POAG) at 3 and 12 months, and with the baseline IOP at 3, 12, 24, and 36 months. Kaplan–Meier analysis demonstrated that the percentage of patients who remained on treatment with DTFC was 94.7%, 94.7%, 84.2%, 78.9%, and 78.9% at 3, 6, 12, 24, and 36 months, respectively. Cox proportional hazards analysis showed that the type of glaucoma (POAG) was associated with an increased risk of failure to control the IOP.ConclusionThe IOP-lowering effect of DTFC was demonstrated for 3 years in this study. The baseline IOP had an important influence on the reduction of IOP achieved by DTFC.

show abstract

Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies

Cited by 31 publications

References 9 publications

Changes in intraocular pressure following a switch from latanoprost monotherapy to latanoprost/timolol fixed combination therapy in patients with primary open-angle glaucoma or ocular hypertension: results from a clinical practice database

Changes in intraocular pressure following a switch from latanoprost monotherapy to latanoprost/timolol fixed combination therapy in patients with primary open-angle glaucoma or ocular hypertension: results from a clinical practice database

Success rates for switching to dorzolamide/timolol fixed combination in timolol responders who are insufficiently controlled by latanoprost monotherapy

Effect of 3 years of treatment with a dorzolamide/timolol (1%/0.5%) combination on intraocular pressure

Contact Info

Product

Resources

About

Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies

Cited by 31 publications

References 9 publications

Changes in intraocular pressure following a switch from latanoprost monotherapy to latanoprost/timolol fixed combination therapy in patients with primary open-angle glaucoma or ocular hypertension: results from a clinical practice database

Changes in intraocular pressure following a switch from latanoprost monotherapy to latanoprost/timolol fixed combination therapy in patients with primary open-angle glaucoma or ocular hypertension: results from a clinical practice database

Success rates for switching to dorzolamide/timolol fixed combination in timolol responders who are insufficiently controlled by latanoprost monotherapy

Effect of 3&nbsp;years of treatment with a dorzolamide/timolol (1%/0.5%) combination on intraocular pressure

Contact Info

Product

Resources

About

Effect of 3 years of treatment with a dorzolamide/timolol (1%/0.5%) combination on intraocular pressure